Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
Roche pulls extended use application for kidney cancer drugRoche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy Share XRoche pulls extended use application for kidney cancer drughttps://pharmaphorum.com/news/roche-pulls-extended-use-application-for-kidney-cancer-drug/
EU approves Ipsen’s Cabometyx in second line liver cancerThe European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The Share XEU approves Ipsen’s Cabometyx in second line liver cancerhttps://pharmaphorum.com/news/european-commission-cabometyx/
ESMO round-up: Big win for AstraZeneca in ovarian cancer, and moreSeveral drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich. Share XESMO round-up: Big win for AstraZeneca in ovarian cancer, and morehttps://pharmaphorum.com/views-and-analysis/esmo-round-up-big-win-for-astrazeneca-in-ovarian-cancer-and-more/
First line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayCompetition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO Share XFirst line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayhttps://pharmaphorum.com/news/first-line-kidney-cancer-inlyta-bavencio/
Merck aims for first line kidney cancer use for Keytruda comboMerck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing Share XMerck aims for first line kidney cancer use for Keytruda combohttps://pharmaphorum.com/news/merck-aims-for-first-line-kidney-cancer-use-for-keytruda-combo/
Pfizer/Merck KGaA eye fast review for kidney cancer comboA combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage Share XPfizer/Merck KGaA eye fast review for kidney cancer combohttps://pharmaphorum.com/news/pfizer-merck-kgaa-eye-fast-review-bavencio/
